

LEGISLATIVE FISCAL OFFICE
Fiscal Note



Fiscal Note On: **HB 392** HLS 24RS 335

Bill Text Version: **REENGROSSED**

Opp. Chamb. Action: **W/ SEN FLOOR AMD**

Proposed Amd.:

Sub. Bill For.:

Date: May 21, 2024	8:33 AM	Author: FREEMAN
Dept./Agy.: LDH		Analyst: Shawn Hotstream
Subject: Medicaid coverage		

MEDICAID

REF NO IMPACT See Note

Page 1 of 1

Provides relative to Medicaid and private insurance coverage for perimenopausal and menopausal care

Proposed law provides for Medicaid coverage of hormonal care for any woman who is experiencing menopausal or perimenopausal symptoms. Proposed law defines symptoms. The department shall cover inpatient and outpatient coverage for perimenopausal or menopausal treatment when such care is used for a medically accepted indication and administered in any healthcare facility by any healthcare professional appropriately licensed in the state to provide such medical treatment. The eligibility of a prospective enrollee shall be determined by the healthcare facility providing the care.

Proposed law requires a health insurance issuer offering health coverage plans in the state to provide coverage for expenses incurred for medically necessary menopausal or perimenopausal treatment. A health insurance issuer shall not require a prior authorization or otherwise subject to a step-therapy or fail first policy or protocol for the administration or prescription of any medication administered or prescribed for hormone replacement therapy used to treat symptoms of menopause and perimenopause.

EXPENDITURES	2024-25	2025-26	2026-27	2027-28	2028-29	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

REVENUES	2024-25	2025-26	2026-27	2027-28	2028-29	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

Information provided by the Office of Group Benefits indicates all five of their self-funded health plans already provide coverage for medically necessary perimenopausal and menopausal care. However, a provision of this measure removes prior authorization or step therapy protocols for any medication administered or prescribed for hormone replacement therapy used to treat symptoms of menopause. The LFO is waiting on a response from OGB relative to this provision of the bill potentially impacting premium rate adjustments.

There is no anticipated direct material effect on Medicaid expenditures as a result of this measure. The Louisiana Department of Health (LDH) indicates Medicaid currently covers such services based on medical necessity. Medicaid covers treatments (non-hormonal treatments, hormonal treatments with a prior authorization, prescription medications, preventive care, counseling, and support) for menopausal and perimenopausal symptoms. Medicaid does not cover experimental/investigational drugs, procedures, or equipment, nor assisted reproductive technology for the treatment of infertility or decreased fertility.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate

Dual Referral Rules

- 13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}
- 13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

House

- 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}
- 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Patrice Thomas
Deputy Fiscal Officer